| Abaloparatide for treating idiopathic or hypogonadal osteoporosis in men [ID4059] | Technology appraisal guidance | TBC |
| Abemaciclib with fulvestrant for previously treated hormone receptor-positive HER2-negative advanced breast cancer TSID 12065 | Technology appraisal guidance | TBC |
| Abicipar pegol for treating wet age-related macular degeneration ID1533 | Technology appraisal guidance | TBC |
| Abiraterone (originator and generics) for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer (review of TA721) [ID6378] | Technology appraisal guidance | TBC |
| Abortion Care | NICE guideline | |
| Acalabrutinib and venetoclax with or without obinutuzumab for untreated chronic lymphocytic leukaemia ID6232 | Technology appraisal guidance | TBC |
| Acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma [ID6155] | Technology appraisal guidance | |
| Acoramidis for treating transthyretin-related amyloidosis cardiomyopathy ID6354 | Technology appraisal guidance | TBC |
| Adagrasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer [ID6339] | Technology appraisal guidance | |
| Advanced breast cancer: diagnosis and management (Partial update) | NICE guideline | TBC |
| Aggressive behaviour in people receiving NHS or social care: prevention and management | NICE guideline | TBC |
| Alpelisib with olaparib for treating BRCA wild-type platinum-refractory or -resistant ovarian, fallopian tube or primary peritoneal cancer after 1 to 3 previous treatments [TSID11830] [ID6247] | Technology appraisal guidance | TBC |
| ALXN1840 for treating Wilson disease TS ID 9950 | Technology appraisal guidance | TBC |
| Alzheimer's disease (early) - gantenerumab [ID6142] | Technology appraisal guidance | TBC |
| Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer [ID5110] | Technology appraisal guidance | |
| Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer [ID6256] | Technology appraisal guidance | |
| Amyotrophic lateral sclerosis - SAR443820 [ID6386] | Technology appraisal guidance | TBC |
| Apalutamide with gonadotrophin-releasing hormone agonist and radiotherapy for treating high-risk, localised or locally advanced prostate cancer [ID6215] | Technology appraisal guidance | TBC |
| Arimoclomol for treating Niemann-Pick disease Type C [ID1312] | Highly specialised technology | TBC |
| Artificial intelligence software to help detect and characterise colorectal polyps | Diagnostics guidance | |
| Artificial intelligence technologies to aid the opportunistic detection of vertebral fragility fractures : Early Value Assessment | Health technology evaluation | |
| Asunercept for treating glioblastoma [1301] | Technology appraisal guidance | TBC |
| Atezolizumab (Tecentriq) + bevacizumab (Avastin) + chemotherapy for ovarian cancer TS ID 10701 | Technology appraisal guidance | TBC |
| Atezolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for early triple negative breast cancer [ID6200] | Technology appraisal guidance | TBC |
| Atezolizumab for adjuvant treatment of resected high-risk muscle-invasive urothelial cancer [ID2730] | Technology appraisal guidance | TBC |
| Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer (MA review of TA823) [ID6324] | Technology appraisal guidance | |
| Atezolizumab with bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6148] | Technology appraisal guidance | TBC |
| Atezolizumab with cabozantinib for treating hormone-relapsed metastatic prostate cancer after 1 therapy [ID6203] | Technology appraisal guidance | TBC |
| Atezolizumab with chemotherapy for treating relapsing recurrent advanced triple-negative early breast cancer [ID6152] | Technology appraisal guidance | TBC |
| Aumolertinib for untreated EGFR mutation-positive non-small-cell lung cancer [ID4000] | Technology appraisal guidance | TBC |
| Autologous chondrocyte implantation using 3D collagen matrix (novocart 3D) for treating articular cartilage defects of the knee [ID2707] | Technology appraisal guidance | TBC |
| Avelumab for previously treated platinum-resistant ovarian cancer ID1497 | Technology appraisal guidance | TBC |
| Avelumab for untreated PD-L1 positive recurrent or metastatic non-small-cell lung cancer [ID1261] | Technology appraisal guidance | TBC |
| Avelumab with axitinib for untreated advanced renal cell carcinoma (MA review of TA645) [ID6294] | Technology appraisal guidance | |
| Beating heart mitral valve repair by artificial chordae insertion for mitral regurgitation | Interventional procedures guidance | |
| Bed frames for adults in medical or surgical hospital wards: Late Stage-assessment | Health technology evaluation | |
| Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 4 or more therapies [ID2701] | Technology appraisal guidance | TBC |
| Belantamab mafodotin with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6212 | Technology appraisal guidance | TBC |
| Belantamab mafodotin with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6211 | Technology appraisal guidance | TBC |
| Belzutifan for previously treated advanced renal cell carcinoma [ID6154] | Technology appraisal guidance | TBC |
| Benralizumab for previously treated severe nasal polyps [ID1659] | Technology appraisal guidance | TBC |
| Benralizumab for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis [ID6266] | Technology appraisal guidance | |
| Beremagene geperpavec for treating skin wounds associated with dystrophic epidermolysis bullosa [ID3959] | Technology appraisal guidance | |
| Betula verrucosa (Itulazax 12 SQ-Bet) for treating moderate to severe allergic rhinitis, conjunctivitis, or both, caused by tree pollen ID6462 | Technology appraisal guidance | |
| Bevacizumab in combination with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer [ID1145] | Technology appraisal guidance | |
| BI 907828 for untreated dedifferentiated advanced liposarcoma [ID6296] | Technology appraisal guidance | TBC |
| Bimatoprost implant for treating open angle glaucoma or ocular hypertension when topical treatments are unsuitable [ID6180] | Technology appraisal guidance | TBC |
| Bipolar disorder: assessment and management (extraordinary review) | NICE guideline | TBC |
| Blood transfusion - Tranexamic acid (update) | NICE guideline | |
| Botulinum toxin type A for treating upper or lower limb focal spasticity associated with stroke [ID768] | Technology appraisal guidance | TBC |
| Breast cancer guidelines | NICE guideline | TBC |
| Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma after 2 or more systemic treatments (review of TA677) [ID6325] | Technology appraisal guidance | |
| Burosumab for treating FGF23-related hypophosphataemia in tumour-induced osteomalacia [ID3924 ] | Technology appraisal guidance | TBC |
| Cabotegravir for preventing HIV-1 in adults and young people [ID6255] | Technology appraisal guidance | |
| Cabozantinib for treating advanced hepatocellular carcinoma after prior therapy [ID1243] | Technology appraisal guidance | |
| Cabozantinib for treating advanced neuroendocrine tumours that have progressed after systemic treatment ID6474 | Technology appraisal guidance | |
| Cabozantinib with nivolumab and ipilimumab for untreated intermediate- or poor-risk advanced renal cell carcinoma [ID6330] | Technology appraisal guidance | TBC |
| Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653] | Technology appraisal guidance | TBC |
| Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment [ID6370] | Technology appraisal guidance | |
| Capivasertib with paclitaxel for untreated metastatic triple-negative breast cancer [ID6383] | Technology appraisal guidance | TBC |
| Cardiometabolic disease prevention and treatment guidelines | NICE guideline | TBC |
| Cediranib with olaparib for treating recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer after 3 therapies [ID1639] | Technology appraisal guidance | TBC |
| Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer [ID3949] | Technology appraisal guidance | |
| Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (MA review of HST12) [ID6145] | Highly specialised technology | |
| Chronic heart failure in adults: diagnosis and management - Pharmacological treatment of chronic heart failure | NICE guideline | |
| Ciltacabtagene autoleucel for treating relapsed and lenalidomide-refractory multiple myeloma after 1 to 3 therapies [ID4012] | Technology appraisal guidance | TBC |
| Cimavax for treating wild-type EGFR-positive non-small-cell lung cancer [1259] | Technology appraisal guidance | TBC |
| Cobolimab with dostarlimab and docetaxel for treating advanced non-small-cell lung cancer after anti-PD-L1 treatment and chemotherapy [ID6398] | Technology appraisal guidance | TBC |
| COLOFIT algorithm to guide colorectal cancer pathway referral in primary care: early value assessment | Health technology evaluation | TBC |
| Colon cancer (adjuvant) - irinotecan [ID379] | Technology appraisal guidance | TBC |
| Compression products for treating venous leg ulcers: late stage assessment | Health technology evaluation | |
| Corticosteroid-releasing bioabsorbable stent or spacer insertion during endoscopic sinus surgery to treat chronic rhinosinusitis | Interventional procedures guidance | TBC |
| Cositecan for treating platinum or taxane resistant advanced, mucinous, epithelial ovarian cancer [ID826] | Technology appraisal guidance | TBC |
| Dapagliflozin for treating chronic kidney disease [ID6411] | Technology appraisal guidance | TBC |
| Daprodustat for treating anaemia in people with chronic kidney disease [ID3987] | Technology appraisal guidance | TBC |
| Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated
multiple myeloma when a stem cell transplant is unsuitable [ID3843] | Technology appraisal guidance | |
| Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when an autologous stem cell transplant is suitable ID6249 | Technology appraisal guidance | |
| Darolutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer ID6452 | Technology appraisal guidance | TBC |
| Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults ID1297 | Technology appraisal guidance | TBC |
| Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults ID1297 | Technology appraisal guidance | |
| Datopotamab deruxtecan for previously treated hormone receptor-positive HER2-negative unresectable or metastatic breast cancer [ID6348] | Technology appraisal guidance | TBC |
| Datopotamab deruxtecan for treating advanced non-small-cell lung cancer after platinum-based chemotherapy [ID6241] | Technology appraisal guidance | TBC |
| DCVax-L for treating glioblastoma [ID836] | Technology appraisal guidance | TBC |
| Degarelix before or with radiotherapy for treating high-risk localised and locally advanced hormone-dependent prostate cancer [ID6419] | Technology appraisal guidance | TBC |
| Delandistrogene moxeparvovec for treating Duchenne muscular dystrophy in children 4 to 7 years ID3897 | Technology appraisal guidance | TBC |
| Delgocitinib for treating moderate to severe chronic hand eczema ID6408 | Technology appraisal guidance | |
| Depemokimab for treating severe eosinophilic asthma in people 12 years and over ID6447 | Technology appraisal guidance | TBC |
| Dexmedetomidine for treating agitation associated with bipolar disorder in people 18 to 75 years [TS ID 10725] | Technology appraisal guidance | TBC |
| Dexmedetomidine for treating agitation associated with schizophrenia TS ID 10726 | Technology appraisal guidance | TBC |
| Diabetic retinopathy - ruboxistaurin [ID382] | Technology appraisal guidance | TBC |
| Digital front door technologies to gather information for assessments for NHS Talking Therapies for anxiety and depression: Early Value Assessment | Health technology evaluation | |
| Digital platforms to support cardiac rehabilitation: early value assessment | Health technology evaluation | |
| Digital self-help for people with eating disorders: early value assessment | Health technology evaluation | |
| Digital technologies for managing mild to moderate hip or knee osteoarthritis: early-value assessment | Health technology evaluation | |
| Digital technologies to support smoking cessation in secondary care patients: early value assessment | Health technology evaluation | TBC |
| Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6222] | Technology appraisal guidance | |
| Donidalorsen for preventing hereditary angioedema attacks in people 12 years and over [ID6457] | Technology appraisal guidance | TBC |
| Dostarlimab with platinum-based chemotherapy for advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiency ID6415 | Technology appraisal guidance | |
| Doxecitine–doxribtimine for treating thymidine kinase 2 deficiency in people of any age ID6484 | Highly specialised technology | TBC |
| Doxorubicin nanoparticles for previously treated advanced hepatocellular carcinoma [ID1314] | Technology appraisal guidance | TBC |
| Dupilumab for treating chronic spontaneous urticaria in people 12 years and over [ID4055] | Technology appraisal guidance | TBC |
| Dupilumab for treating moderate to severe chronic obstructive pulmonary disease ID6235 | Technology appraisal guidance | TBC |
| Dupilumab for treating severe chronic rhinosinusitis with nasal polyposis (Review of TA648) [ID6480] | Technology appraisal guidance | |
| Durvalumab for adjuvant treatment of resectable non-small-cell lung cancer [ID1263] | Technology appraisal guidance | TBC |
| Durvalumab for adjuvant treatment of resectable non-small-cell lung cancer [ID1263] | NICE guideline | TBC |
| Durvalumab for treating limited-stage small-cell lung cancer after chemoradiation [ID5073] | Technology appraisal guidance | |
| Durvalumab with chemoradiation for untreated unresectable locally advanced oesophageal squamous cell cancer
[ID6490] | Technology appraisal guidance | TBC |
| Durvalumab with gemcitabine and cisplatin before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating muscle-invasive bladder cancer [ID6168] | Technology appraisal guidance | |
| Durvalumab with platinum-based chemotherapy, then with or without olaparib, for treating newly diagnosed advanced or recurrent endometrial cancer ID6317 | Technology appraisal guidance | |
| Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma [ID2725] | Technology appraisal guidance | |
| Ectopic pregnancy and miscarriage: diagnosis and initial management | NICE guideline | TBC |
| Efgartigimod for treating generalised myasthenia gravis [ID4003] | Technology appraisal guidance | TBC |
| Efgartigimod with recombinant human hyaluronidase PH20 for treating chronic inflammatory demyelinating polyneuropathy ID6409 | Technology appraisal guidance | TBC |
| Eflornithine for treating high-risk neuroblastoma with complete or partial response after immunotherapy [ID4060] | Technology appraisal guidance | |
| Empagliflozin for preventing cardiovascular events after acute myocardial infarction [ID6240] | Technology appraisal guidance | TBC |
| Encorafenib with binimetinib for treating BRAF V600E mutation-positive advanced non-small-cell lung cancer [ID6177] | Technology appraisal guidance | |
| Endoscopic bipolar radiofrequency ablation for treating biliary obstruction caused by cholangiocarcinoma or pancreatic adenocarcinoma | Interventional procedures guidance | TBC |
| Enfortumab vedotin for treating locally advanced or metastatic urothelial cancer after 2 therapies [ID3845] | Technology appraisal guidance | |
| Enfortumab vedotin with pembrolizumab for untreated unresectable or metastatic urothelial cancer when platinum-based chemotherapy is suitable [ID6332] | Technology appraisal guidance | |
| Epcoritamab for treating relapsed or refractory follicular lymphoma after 2 or more systemic treatments [ID6338] | Technology appraisal guidance | TBC |
| Epilepsies in children, young people and adults (extraordinary review) | NICE guideline | TBC |
| ERC1671 for treating progressed or recurrent grade IV glioma (glioblastoma or gliosarcoma) [ID1623] | Technology appraisal guidance | TBC |
| Evolocumab for preventing major cardiovascular events in people aged 50 to 79 at high risk who have not had a myocardial infarction or stroke TS ID 11920 | Technology appraisal guidance | TBC |
| Ex-situ machine perfusion devices for liver transplants: early value assessment | Health technology evaluation | |
| Exploratory economic modelling of SARS-CoV-2 viral detection point of care tests and serology tests | Diagnostics guidance | TBC |
| Familial Breast Cancer: initial assessment and genetic testing (update) | NICE guideline | |
| Favezelimab–pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after anti-PD-L1 treatment [ID6393] | Technology appraisal guidance | TBC |
| Fertility problems: assessment and treatment - update 1 and 2 | NICE guideline | TBC |
| Fezolinetant for treating vasomotor symptoms associated with the menopause [ID5071] | Technology appraisal guidance | TBC |
| Fidanacogene elaparvovec for treating moderately severe to severe haemophilia B [ID4032] | Technology appraisal guidance | TBC |
| Finerenone for treating heart failure with preserved or mildly reduced ejection fraction ID6514 | Technology appraisal guidance | TBC |
| Fordadistrogene movaparvovec for treating Duchenne muscular dystrophy [ID6133] | Technology appraisal guidance | TBC |
| Fosdenopterin for treating molybdenum cofactor deficiency type A [ID6264] | Highly specialised technology | TBC |
| Fruquintinib for previously treated metastatic colorectal cancer ID6274 | Technology appraisal guidance | TBC |
| Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over [ID6394] | Technology appraisal guidance | |
| GID-MT567 Evoke Spinal Cord Stimulator for managing chronic neuropathic or ischaemic pain | Medical technologies guidance | TBC |
| Giroctocogene fitelparvovec for treating moderately severe to severe haemophilia A ID6312 | Technology appraisal guidance | TBC |
| Givinostat for treating Duchenne muscular dystrophy in people 6 years and over [ID6323] | Technology appraisal guidance | |
| Glaucoma - lerdelimumab (CAT-152) [ID383] | Technology appraisal guidance | TBC |
| Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse B-cell lymphoma [ID6202] | Technology appraisal guidance | |
| Glycopyrronium bromide cream for treating severe primary axillary hyperhidrosis ID6487 | Technology appraisal guidance | |
| Guselkumab for previously treated moderately to severely active Crohn's disease ID6238 | Technology appraisal guidance | TBC |
| Guselkumab for treating moderately to severely active ulcerative colitis ID6237 | Technology appraisal guidance | |
| Histamine dihydrochloride with interleukin-2 for maintenance treatment of acute myeloid leukaemia ID1627 | Technology appraisal guidance | TBC |
| Hydromethylthionine mesylate for treating mild cognitive impairment or mild or moderate dementia caused by Alzheimer's disease [ID6343] | Technology appraisal guidance | TBC |
| Ibrutinib for treating relapsed or refractory follicular lymphoma [1251] | Technology appraisal guidance | TBC |
| Iclepertin for treating cognitive impairment associated with schizophrenia [ID6483] | Technology appraisal guidance | TBC |
| Idebenone for treating visual impairment in Leber's hereditary optic neuropathy in people 12 years and over [ID547] | Technology appraisal guidance | |
| Imetelstat for treating relapsed or refractory transfusion-dependent myelodysplastic syndromes [ID3922] | Technology appraisal guidance | TBC |
| Imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy [ID6373] | Technology appraisal guidance | TBC |
| Implanting a baroreceptor stimulation device for resistant hypertension | Interventional procedures guidance | TBC |
| Inavolisib with palbociclib and fulvestrant for treating recurrent hormone receptor-positive HER2-negative PIK3CA-positive advanced breast cancer after adjuvant endocrine treatment [ID6425] | Technology appraisal guidance | TBC |
| Infigratinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement [ID3992] | Technology appraisal guidance | TBC |
| Inhaled treprostinil for treating pulmonary hypertension with interstitial lung disease ID6459 | Technology appraisal guidance | |
| Insertion of a catheter-based intravascular microaxial flow pump for cardiogenic shock | Interventional procedures guidance | |
| Insulin icodec for treating type 2 diabetes [ID6175] | Technology appraisal guidance | TBC |
| Intermittent urethral catheters for chronic incomplete bladder emptying in adults: late-stage assessment | Health technology evaluation | TBC |
| Intrapartum Care - maternal hyponatremia | NICE guideline | |
| Intrapartum Care - Water birth: second stage of labour | NICE guideline | TBC |
| Iodine (131I)–apamistamab for treating relapsed or refractory acute myeloid leukaemia before an allogeneic haematopoietic stem cell transplant [ID6355] | Technology appraisal guidance | TBC |
| Ipatasertib with abiraterone and prednisone for hormone-relapsed metastatic prostate cancer [ID3889] | Technology appraisal guidance | TBC |
| Iptacopan for treating complement 3 glomerulopathy [ID6283] | Technology appraisal guidance | |
| Isatuximab in combination for untreated multiple myeloma when a stem cell transplant is unsuitable ID3981 | Technology appraisal guidance | |
| Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma [Review of TA658] [ID4067] | Technology appraisal guidance | |
| Ixazomib citrate for maintenance treatment of untreated multiple myeloma after autologous stem cell transplant [ID1517] | Technology appraisal guidance | TBC |
| Ixazomib citrate for maintenance treatment of untreated multiple myeloma in people who cannot have autologous stem cell transplant [ID2706] | Technology appraisal guidance | TBC |
| Kidney Cancer | NICE guideline | TBC |
| Lacosamide for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy [ID1687] | Technology appraisal guidance | TBC |
| Laparoscopic insertion of an inactive implant for gastro-oesophageal reflux disease | Interventional procedures guidance | |
| Lazertinib with amivantamab and platinum-based chemotherapy for EGFR mutation-positive metastatic non-small-cell lung cancer after a tyrosine kinase inhibitor [ID6305] | Technology appraisal guidance | TBC |
| Leadless cardiac pacemaker implantation for bradyarrhythmias | Interventional procedures guidance | |
| Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID4043] | Technology appraisal guidance | |
| Lenacapavir for preventing HIV-1 in people aged 16 years or older ID6495 | Technology appraisal guidance | |
| Lenadogene nolparvovec for treating Leber's hereditary optic neuropathy caused by the G11778A ND4 mitochondrial mutation [ID1410] | Technology appraisal guidance | TBC |
| Leriglitazone for treating andrenoleukodystrophy [ID3903] | Technology appraisal guidance | TBC |
| Letermovir for preventing cytomegalovirus infection after a kidney transplant [ID6166] | Technology appraisal guidance | TBC |
| Leukocyte interleukin in combination for neoadjuvant treatment of resectable locally advanced squamous cell head and neck cancer [ID6390] | Technology appraisal guidance | TBC |
| Lifileucel for previously treated unresectable or metastatic melanoma ID3863 | Technology appraisal guidance | |
| Linzagolix for treating symptoms of endometriosis [ID6357] | Technology appraisal guidance | |
| Lisocabtagene maraleucel for treating relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6174] | Technology appraisal guidance | TBC |
| Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer (Review of TA909) [ID6434] | Technology appraisal guidance | |
| Low energy contact X-ray brachytherapy (the Papillon technique) for rectal cancer | Interventional procedures guidance | |
| Low-dose atropine eye drops for treating myopia in people 3 to 14 years [ID6517] | Technology appraisal guidance | TBC |
| Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (in combination with bevacizumab) [ID44] | Technology appraisal guidance | TBC |
| Lung cancer (non-small-cell, advanced or metastatic second line) - erlotinib (in combination with bevacizumab) [ID43] | Technology appraisal guidance | TBC |
| Lurbinectedin for treating advanced platinum-resistant ovarian cancer ID1340 | Technology appraisal guidance | TBC |
| Lurbinectedin for treating advanced small-cell lung cancer on or after platinum-based chemotherapy [ID3872] | Technology appraisal guidance | TBC |
| Managing common infections - antimicrobial prescribing guidelines | NICE guideline | TBC |
| Maralixibat for treating cholestatic pruritus in Alagille syndrome [ID3941] | Technology appraisal guidance | TBC |
| Maralixibat for treating progressive familial intrahepatic cholestasis [ID3818] | Technology appraisal guidance | TBC |
| Marstacimab for treating severe haemophilia A or severe haemophilia B in people 12 years and over [ID6342] | Technology appraisal guidance | |
| Masitinib with riluzole for treating amyotrophic lateral sclerosis [ID6257] | Technology appraisal guidance | TBC |
| Mavacamten for treating symptomatic non-obstructive hypertrophic cardiomyopathy
[ID6523] | Technology appraisal guidance | TBC |
| Melanoma (metastatic) - talimogene laherparepvec [ID508] | Technology appraisal guidance | |
| Mental health guidelines | NICE guideline | TBC |
| Mepolizumab for reducing eosinophilic exacerbations of chronic obstructive pulmonary disease ID1237 | Technology appraisal guidance | TBC |
| Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | NICE guideline | TBC |
| Mirikizumab for treating moderately to severely active Crohn's disease [ID6244] | Technology appraisal guidance | TBC |
| Mirvetuximab soravtansine for previously treated platinum-resistant FR-alpha positive ovarian cancer [ID1527] | Technology appraisal guidance | TBC |
| Mirvetuximab soravtansine for treating folate receptor alpha-positive platinum-resistant advanced epithelial ovarian, fallopian tube or primary peritoneal cancer [ID6442] | Technology appraisal guidance | |
| MTX110 for untreated diffuse intrinsic pontine glioma [ID2695] | Technology appraisal guidance | TBC |
| Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy [ID6369] | Technology appraisal guidance | |
| Navitoclax with ruxolitinib for treating myelofibrosis when stem cell transplant is unsuitable [ID5096] | Technology appraisal guidance | TBC |
| Nemolizumab for treating moderate to severe atopic dermatitis in people 12 years and over ID6221 | Technology appraisal guidance | |
| Nemolizumab for treating prurigo nodularis [ID6451] | Technology appraisal guidance | TBC |
| Neuroendocrine tumours (metastatic, unresectable, progressive) - everolimus and sunitinib [ID858] | Technology appraisal guidance | |
| Nintedanib for treating fibrosing interstitial lung disease in people aged 6 to 17 [ID6194] | Technology appraisal guidance | TBC |
| Nirogacestat for treating desmoid tumours [ID6453] | Technology appraisal guidance | TBC |
| Nitazoxanide for treating the common cold in people 12 years and over [ID4049] | Technology appraisal guidance | TBC |
| Nivolumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID6310] | Technology appraisal guidance | |
| Nivolumab for adjuvant treatment of high-risk hepatocellular carcinoma after liver resection or ablation [ID3858] | Technology appraisal guidance | |
| Nivolumab for adjuvant treatment of resected non-small-cell lung cancer [ID4053] | Technology appraisal guidance | TBC |
| Nivolumab with chemotherapy for untreated unresectable or metastatic urothelial cancer [ID5102] | Technology appraisal guidance | TBC |
| Nivolumab with ipilimumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1136] | Technology appraisal guidance | |
| Nivolumab with ipilimumab for untreated unresectable or metastatic urothelial cancer when cisplatin is unsuitable [ID3939] | Technology appraisal guidance | TBC |
| Nivolumab with ipilimumab for untreated unresectable stage 3 non-small-cell lung cancer [ID6248] | Technology appraisal guidance | TBC |
| Non-invasive skin closure devices for surgical incisions (MT775) | Medical technologies guidance | TBC |
| Nusinersen and risdiplam for treating spinal muscular atrophy (review of TA588 and TA755) [ID6195] | Technology appraisal guidance | TBC |
| NY-ESO-1 T-cells for treating synovial sarcoma ID1286 | Technology appraisal guidance | TBC |
| Obecabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia [ID6347] | Technology appraisal guidance | |
| Obeticholic acid for treating liver fibrosis in people with steatohepatitis [ID1645] | Technology appraisal guidance | TBC |
| Obinutuzumab with immunosuppressive therapies for treating lupus nephritis [ID6420] | Technology appraisal guidance | |
| Obsessive-compulsive disorder and body dysmorphic disorder: assessment and management | NICE guideline | TBC |
| Odevixibat for treating cholestasis and pruritus in Alagille Syndrome [ID6181] | Technology appraisal guidance | TBC |
| Omburtamab for treating relapsed neuroblastoma [ID1664] | Technology appraisal guidance | TBC |
| One-piece closed bags for colostomies: Late Stage Assessment | Health technology evaluation | |
| Optical Coherence Tomography to guide percutaneous coronary intervention | Interventional procedures guidance | TBC |
| Oral paclitaxel with encequidar for treating advanced breast cancer [ID5111] | Technology appraisal guidance | TBC |
| OrganOx metra for liver transplant [ID5116] | Technology appraisal guidance | TBC |
| Osimertinib for maintenance treatment of EGFR mutation-positive locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation [ID6223] | Technology appraisal guidance | |
| Osteoporosis: risk assessment, treatment, and fragility fracture prevention (update) | NICE guideline | TBC |
| Oxybutynin hydrochloride for managing neurogenic detrusor overactivity in people 6 years and over with spinal cord injury or spina bifida [ID5089] | Technology appraisal guidance | TBC |
| Palbociclib with trastuzumab and endocrine therapy for maintenance treatment of hormone-receptor positive, HER2-positive metastatic breast cancer [ID6251] | Technology appraisal guidance | TBC |
| Palforzia for treating peanut allergy in children aged 1 to 3 [ID6144] | Technology appraisal guidance | TBC |
| Palopegteriparatide for treating chronic hypoparathyroidism [ID6380] | Technology appraisal guidance | |
| Peezy Midstream for urine collection (MT446) | Medical technologies guidance | TBC |
| Pegcetacoplan for amyotrophic lateral sclerosis TS ID 10594 | Technology appraisal guidance | TBC |
| Pegcetacoplan for treating geographic atrophy [ID4041] | Technology appraisal guidance | TBC |
| Pegcetacoplan for treating primary complement 3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis in people 12 years and over [ID6489] | Technology appraisal guidance | TBC |
| Pegzilarginase for treating arginase-1 deficiency [ID4029] | Highly specialised technology | TBC |
| Pembrolizumab for adjuvant treatment of locally advanced cutaneous squamous cell carcinoma after surgery and radiotherapy ID 6473 | Technology appraisal guidance | TBC |
| Pembrolizumab with carboplatin and paclitaxel for untreated advanced or recurrent endometrial cancer [ID6381] | Technology appraisal guidance | TBC |
| Pembrolizumab with chemoradiation for untreated high-risk locally advanced cervical cancer [ID6138] | Technology appraisal guidance | |
| Pembrolizumab with chemoradiation, then with or without olaparib, for untreated unresectable locally advanced non-small-cell lung cancer [ID6399] | Technology appraisal guidance | TBC |
| Pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial cancer after surgery with curative intent [ID6207] | Technology appraisal guidance | TBC |
| Pembrolizumab with chemotherapy for treating platinum-resistant recurrent ovarian cancer after 1 or 2 treatments [ID6363] | Technology appraisal guidance | TBC |
| Pembrolizumab with ipilimumab for treating PD-L1-positive advanced non-small-cell lung cancer [ID3861] | Technology appraisal guidance | TBC |
| Pembrolizumab with lenvatinib and chemotherapy for untreated advanced gastro-oesophageal junction cancer [TSID11861] | Technology appraisal guidance | TBC |
| Pembrolizumab with olaparib for treating hormone-relapsed metastatic prostate cancer after abiraterone or enzalutamide and chemotherapy [ID3814] | Technology appraisal guidance | TBC |
| Pembrolizumab with pemetrexed and platinum-based chemotherapy for untreated unresectable advanced malignant pleural mesothelioma [ID4044] | Technology appraisal guidance | TBC |
| Pembrolizumab with stereotactic body radiotherapy for treating unresected stage 1 or 2 non-small-cell lung cancer [ID6149] | Technology appraisal guidance | TBC |
| Pembrolizumab–vibostolimab for untreated metastatic non-small-cell lung cancer [ID6365] | Technology appraisal guidance | TBC |
| Pembrolizumab–vibostolimab with etoposide and platinum-based chemotherapy for untreated extensive-stage small-cell lung cancer [ID6361] | Technology appraisal guidance | TBC |
| Pertuzumab–trastuzumab with chemotherapy for treating HER2-positive breast cancer [ID2724] | Technology appraisal guidance | TBC |
| PillCam COLON 2 for investigation of the colon through direct visualisation | Diagnostics guidance | |
| Pirtobrutinib for treating chronic lymphocytic leukaemia or small lymphocytic lymphoma after 1 or more BTK inhibitors [ID6269] | Technology appraisal guidance | |
| Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma [ID3975] | Technology appraisal guidance | TBC |
| Pirtobrutinib for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6397] | Technology appraisal guidance | TBC |
| Pneumonia: diagnosis and management (update) | NICE guideline | |
| Polihexanide eye drops for treating acanthamoeba keratitis in people 12 years and over [ID6497] | Technology appraisal guidance | |
| Polycystic ovary syndrome: assessment and management | NICE guideline | TBC |
| Port Delivery platform with ranibizumab for treating wet age-related macular degeneration [ID3983] | Technology appraisal guidance | TBC |
| Pridopidine for treating Huntington's disease [ID6525] | Technology appraisal guidance | TBC |
| Pulmonary artery pressure technologies for remote monitoring of chronic heart failure | Diagnostics guidance | |
| Pulsed field ablation for atrial fibrillation | Interventional procedures guidance | |
| Regorafenib for treating advanced gastrointestinal stromal tumours [ID1056] | Technology appraisal guidance | |
| Rehabilitation for chronic neurological disorders including acquired brain injury | NICE guideline | |
| Renal cell carcinoma Pathways Pilot [ID6186] | Technology appraisal guidance | TBC |
| Repotrectinib for treating NTRK fusion-positive advanced solid tumours in people 12 years and over [TSID12147] | Technology appraisal guidance | TBC |
| Repotrectinib for treating ROS1-positive advanced non-small-cell lung cancer [ID6277] | Technology appraisal guidance | TBC |
| Resmetirom and semaglutide for treating metabolic dysfunction-associated steatohepatitis with liver fibrosis ID6458 | Technology appraisal guidance | TBC |
| Retifanlimab with chemotherapy for untreated PD-L1-positive metastatic non-small-cell lung cancer TSID 12007 | Technology appraisal guidance | TBC |
| Ribociclib in combination with endocrine therapy and goserelin for previously untreated hormone receptor-positive, HER2-negative advanced breast cancer in premenopausal women (ID1307) | Technology appraisal guidance | TBC |
| Ribociclib with an aromatase inhibitor for adjuvant treatment of hormone receptor-positive, HER2-negative early breast cancer [ID6153] | Technology appraisal guidance | |
| Rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1601] | Technology appraisal guidance | TBC |
| Rivogenlecleucel for treating haematological non-malignant diseases in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1496] | Technology appraisal guidance | TBC |
| Ropeginterferon alfa-2b for treating polycythaemia vera without symptomatic splenomegaly [ID1596] | Technology appraisal guidance | TBC |
| Rozanolixizumab for treating antibody-positive generalised myasthenia gravis [ID5092] | Technology appraisal guidance | TBC |
| Ruxolitinib for Prurigo Nodularis [ID6571] | Technology appraisal guidance | TBC |
| Ruxolitinib for treating moderate to severe chronic graft-versus-host disease after an allogeneic stem cell transplant in people 28 days to 17 years [ID6427] | Technology appraisal guidance | TBC |
| Ruxolitinib for treating non-segmental vitiligo in people 12 years and over [ID3998] | Technology appraisal guidance | TBC |
| Sacituzumab govitecan for treating advanced non-small-cell lung cancer after platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor [ID6375] | Technology appraisal guidance | TBC |
| Sacituzumab govitecan for treating hormone receptor-positive HER2-negative metastatic breast cancer after 2 or more therapies [ID4033] | Technology appraisal guidance | TBC |
| Sacituzumab govitecan for treating unresectable metastatic urothelial cancer [ID6150] | Technology appraisal guidance | TBC |
| Sebetralstat for treating acute attacks of hereditary angioedema in people aged 12 and over [ID6284] | Technology appraisal guidance | |
| Secukinumab for treating enthesitis-related arthritis or juvenile psoriatic arthritis [ID3738] | Technology appraisal guidance | TBC |
| Seladelpar for previously treated primary biliary cholangitis ID6429 | Technology appraisal guidance | |
| Selpercatinib for treating RET fusion-positive advanced solid tumours in people aged 12 and over with no other treatment options [ID6273] | Technology appraisal guidance | TBC |
| Selpercatinib for untreated RET-positive advanced thyroid cancer [ID6183] | Technology appraisal guidance | TBC |
| Semaglutide for managing overweight and obesity and the reduction of associated cardiovascular risk (ID6441 including a review of TA875 and TA910) | Technology appraisal guidance | TBC |
| Serplulimab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer [ID6346] | Technology appraisal guidance | |
| Sipavibart for preventing COVID 19 [ID6282] | Technology appraisal guidance | TBC |
| Sirolimus gel for treating facial angiofibroma from tuberous sclerosis complex in people 6 years and older (review of TA972) [ID6440] | Technology appraisal guidance | |
| Sodium zirconium cyclosilicate for treating hyperkalaemia (partial review of TA599) [ID6439] | Technology appraisal guidance | |
| Somapacitan for treating growth hormone deficiency in people 3 to 17 years [ID6178] | Technology appraisal guidance | |
| Sotatercept for treating pulmonary arterial hypertension [ID6163] | Technology appraisal guidance | |
| Soticlestat for treating seizures associated with Dravet syndrome in people 2 years and over TSID 12091 | Technology appraisal guidance | TBC |
| Soticlestat for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over TSID 10632 | Technology appraisal guidance | TBC |
| Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (MA review of TA781) [ID6287] | Technology appraisal guidance | |
| SpaceOAR hydrogel spacer for reducing rectal toxicity during radiotherapy for prostate cancer (Suspended – referred to technology appraisals) | Medical technologies guidance | TBC |
| Sparsentan for treating primary IgA nephropathy [ID6308] | Technology appraisal guidance | |
| Spartalizumab with dabrafenib and trametinib for untreated BRAF V600 mutation-positive unresectable or metastatic melanoma [ID1668] | Technology appraisal guidance | |
| Spesolimab for preventing generalised pustular psoriasis flares [ID6216] | Technology appraisal guidance | TBC |
| Spesolimab for preventing generalised pustular psoriasis flares in people 12 years and over [TSID12086] | Technology appraisal guidance | TBC |
| Spesolimab for treating generalised pustular psoriasis flares [ID3963] | Technology appraisal guidance | |
| Sugemalimab with chemotherapy for untreated metastatic non-small-cell lung cancer [ID4001] | Technology appraisal guidance | TBC |
| Surgical vessel sealing systems (MT798) | Medical technologies guidance | TBC |
| Suspected Cancer | NICE guideline | TBC |
| Suspected sepsis: recognition, diagnosis and early management | NICE guideline | TBC |
| Suspected sepsis: recognition, diagnosis and early management | NICE guideline | |
| Talacotuzumab for untreated acute myeloid leukaemia [ID1262] | Technology appraisal guidance | TBC |
| Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer [ID4004] | Technology appraisal guidance | |
| Talquetamab for treating relapsed or refractory multiple myeloma after 3 treatments [ID5082] | Technology appraisal guidance | |
| Targeted muscle reinnervation for managing limb amputation pain | Interventional procedures guidance | |
| Targeted-release budesonide for treating primary IgA nephropathy (review of TA937) [ID6485] | Technology appraisal guidance | |
| Tarlatamab for previously treated advanced small-cell lung cancer [ID6364] | Technology appraisal guidance | |
| Taselisib for previously treated ER-positive, HER2-negative, PIK3CA-positive breast cancer in postmenopausal women ID1401 | Technology appraisal guidance | TBC |
| Telisotuzumab vedotin for treating c-MET overexpressed, EGFR wild-type, non-squamous advanced non-small-cell lung cancer after 1 or more systemic treatments [ID6253] | Technology appraisal guidance | TBC |
| Teplizumab for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes [ID6259] | Technology appraisal guidance | |
| Teprotumumab for treating thyroid eye disease [ID6432] | Technology appraisal guidance | |
| Third molars (impacted) - prophylactic removal [ID898] | Technology appraisal guidance | TBC |
| Tislelizumab for treating advanced non-small-cell lung cancer after platinum-based chemotherapy ID6161 | Technology appraisal guidance | TBC |
| Tislelizumab for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy [ID4070] | Technology appraisal guidance | TBC |
| Tislelizumab with chemotherapy for untreated advanced oesophageal squamous cell cancer ID5113 | Technology appraisal guidance | TBC |
| Tisotumab vedotin for treating recurrent or metastatic cervical cancer after chemotherapy ID3753 | Technology appraisal guidance | TBC |
| Tofersen for treating amyotrophic lateral sclerosis caused by SOD1 gene mutations [ID3767] | Highly specialised technology | TBC |
| Tolebrutinib for treating secondary progressive multiple sclerosis ID6351 | Technology appraisal guidance | TBC |
| Topical antimicrobial dressings for locally infected leg ulcers: Late stage assessment | Health technology evaluation | TBC |
| Topical rapamycin for treating facial angiofibromas associated with tuberous sclerosis complex in people 6 years and over [ID6391] | Technology appraisal guidance | TBC |
| Total hip arthroplasty using the superpath approach for osteoarthritis | Interventional procedures guidance | TBC |
| Transcatheter aortic valve implantation for native aortic valve regurgitation | Interventional procedures guidance | |
| Transcatheter heart valves for transcatheter aortic valve implantation to treat aortic stenosis: Late stage assessment | Health technology evaluation | TBC |
| Transcatheter tricuspid valve implantation for tricuspid regurgitation | Interventional procedures guidance | |
| Transvenous embolisation for treating cerebrospinal fluid venous fistula associated with spontaneous intracranial hypotension | Interventional procedures guidance | |
| Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments [ID6309] | Technology appraisal guidance | |
| Treatments for non-small-cell lung cancer [ID6234] | Technology appraisal guidance | TBC |
| Tucatinib with trastuzumab emtansine for treating HER2-positive unresectable or advanced breast cancer after a taxane, trastuzumab or both together [ID6165] | Technology appraisal guidance | TBC |
| Tucatinib with trastuzumab for previously treated HER2-positive colorectal cancer [ID6227] | Technology appraisal guidance | TBC |
| Type 2 diabetes in adults: management (medicines update) | NICE guideline | |
| Upadacitinib for treating giant cell arteritis [ID6299] | Technology appraisal guidance | |
| Vanzacaftor–tezacaftor–deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people aged 6 years and over [ID6372] | Technology appraisal guidance | |
| Veliparib with carboplatin and paclitaxel for untreated non-squamous non-small-cell lung cancer [ID1277] | Technology appraisal guidance | TBC |
| Venetoclax with azacitidine for untreated high-risk myelodysplastic syndromes [ID6314] | Technology appraisal guidance | TBC |
| Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia when there is no 17p deletion or TP53 mutation and FCR (fludarabine, cyclophosphamide, rituximab) or BR (bendamustine, rituximab) are suitable (MA partial review of TA663) [ID6291] | Technology appraisal guidance | |
| Venglustat for treating gangliosidoses in people 2 years and over ID 6358 | Technology appraisal guidance | TBC |
| Venoarterial extracorporeal membrane oxygenation (VA ECMO) for acute heart failure in adults | Interventional procedures guidance | |
| Venoarterial Extracorporeal membrane oxygenation (VA ECMO) for extracorporeal cardiopulmonary resuscitation (ECPR) in adults in refractory cardiac arrest | Interventional procedures guidance | |
| Vepdegestrant for treating hormone receptor-positive HER2-negative metastatic breast cancer after endocrine treatment [ID6360] | Technology appraisal guidance | TBC |
| Vibostolimab–pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID6382] | Technology appraisal guidance | TBC |
| Vimseltinib for treating tenosynovial giant cell tumours when surgery is unsuitable TSID 12099 | Technology appraisal guidance | TBC |
| Vocimagene amiretrorepvec with extended-release 5-fluorocytosine for treating recurrent high-grade glioma [ID1425] | Technology appraisal guidance | TBC |
| Vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over [ID6407] | Technology appraisal guidance | |
| Vosoritide for treating achondroplasia in people 4 months and over ID6488 | Technology appraisal guidance | TBC |
| VTS-270 for treating Niemann-Pick type C1 [ID1267] | Highly specialised technology | TBC |
| Vutrisiran for treating transthyretin-related amyloidosis cardiomyopathy [ID6470] | Technology appraisal guidance | |
| Waldenstrom's macroglobulinaemia - ibrutinib [ID884] | Technology appraisal guidance | |
| Women's and reproductive health guidelines | NICE guideline | TBC |
| Xevinapant with platinum-based chemotherapy and radiotherapy for untreated locally advanced squamous cell head and neck cancer [ID6199] | Technology appraisal guidance | TBC |
| Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more systemic treatments [ID6388] | Technology appraisal guidance | |
| Zanubrutinib for treating relapsed or refractory mantle cell lymphoma after 1 or more treatments [ID6392] | Technology appraisal guidance | |
| Zanubrutinib for untreated chronic lymphocytic leukaemia [ID5079] | Technology appraisal guidance | TBC |
| Zilucoplan for treating antibody positive generalised myasthenia gravis [ID4008] | Technology appraisal guidance | TBC |
| Zio XT for detecting cardiac arrhythmias | Medical technologies guidance | TBC |
| Zuranolone for treating postnatal depression [ID6431] | Technology appraisal guidance | |
| Venoarterial Extracorporeal membrane oxygenation (VA ECMO) for postcardiotomy cardiogenic shock in adults | Interventional procedures guidance | |